Drugs / AR51 (12, 10)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00551629 | May 2001 → Mar 2003 | — | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 2 | NCT00551915 | May 2001 → Jan 2003 | — | Merck Sharp & Dohme LLC | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR51 (12, 10) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00551915 ↗ |
| Route | Intramuscular | “via intramuscular injection” NCT00551629 ↗ |